Acute Leukemia Evolution and Survival Time of MDS Patients Within Subgroups Identified by Different Scoring Systems and the FAB Classification
. | Risk Category . | ||||||
---|---|---|---|---|---|---|---|
. | Low . | Intermediate . | High . | . | . | ||
. | . | . | . | . | . | . | . |
A. Median survival (mo) | |||||||
Prognostic system | |||||||
Mufti | 32.7 | 17.6 | 11.9 | ||||
Sanz | 64.3 | 14.4 | 11.9 | ||||
Goasquen | 50.1 | 32.7 | 11.9 | 15.1 | |||
Morra | 39.6 | 12.3 | 15.7 | 11.9 | |||
Morel | 62.3 | 16.8 | 12.4 | ||||
IPSS | 40.6 | 25.8 | 14.9 | 10.4 | |||
FAB | 52.1 | 17.1 | 10.5 | ||||
B. 25% acute leukemia evolution (mo) | |||||||
Prognostic system | |||||||
Mufti | NR | 8.3 | 6.2 | ||||
Sanz | NR | 9.5 | 4.2 | ||||
Goasguen | NR | 23.6 | 6.4 | 8.9 | |||
Morra | 18.5 | 7.0 | 10.6 | 5.0 | |||
Morel | NR | 8.8 | 6.0 | ||||
IPSS | NR | 17.7 | 8.6 | 5.0 | |||
FAB | NR | 9.2 | 4.7 |
. | Risk Category . | ||||||
---|---|---|---|---|---|---|---|
. | Low . | Intermediate . | High . | . | . | ||
. | . | . | . | . | . | . | . |
A. Median survival (mo) | |||||||
Prognostic system | |||||||
Mufti | 32.7 | 17.6 | 11.9 | ||||
Sanz | 64.3 | 14.4 | 11.9 | ||||
Goasquen | 50.1 | 32.7 | 11.9 | 15.1 | |||
Morra | 39.6 | 12.3 | 15.7 | 11.9 | |||
Morel | 62.3 | 16.8 | 12.4 | ||||
IPSS | 40.6 | 25.8 | 14.9 | 10.4 | |||
FAB | 52.1 | 17.1 | 10.5 | ||||
B. 25% acute leukemia evolution (mo) | |||||||
Prognostic system | |||||||
Mufti | NR | 8.3 | 6.2 | ||||
Sanz | NR | 9.5 | 4.2 | ||||
Goasguen | NR | 23.6 | 6.4 | 8.9 | |||
Morra | 18.5 | 7.0 | 10.6 | 5.0 | |||
Morel | NR | 8.8 | 6.0 | ||||
IPSS | NR | 17.7 | 8.6 | 5.0 | |||
FAB | NR | 9.2 | 4.7 |
For the FAB classification: low risk, RA + RARS; intermediate risk RAEB; high risk, RAEB-t + CMML.
Abbreviation: NR, not reached.